

EDITORIAL BOARD

Leanne Alworth, DVM, MS, DACLAM

Assistant Director/Attending Veterinarian
University of Georgia, Athens, GA

Lida Anestidou, DVM, PhD

Program Officer, Institute for Laboratory Animal Medicine,
The National Academies, Washington, DC

Cyndi Brown, DVM, DABVP (Avian Practice)

Ocean State Veterinary Specialists, East Greenwich, RI

Thomas M. Donnelly, DVM, DACLAM

The Kenneth S. Warren Institute, Ossining, NY

Paul Houghton

CEO, Biologist, Primate Products, Redwood City, CA

Robert F. Hoyt, Jr., DVM, MS, DACLAM

Chief, Laboratory Animal Medicine and Surgery,
National Heart Lung and Blood Institute, NIH, Bethesda, MD

Mary Lou James, BA, RLATG

Consultant, Regulatory Compliance, St. Louis, MO

Alicia Z. Karas, DVM, MS, DACVA

Assistant Professor, Anesthesia, Department of Clinical Sciences,
Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA

Bruce W. Kennedy, MS, RLAT G, CMAR, CPIA

Compliance Associate and Lecturer, Office of Research,
Cal Poly Pomona, Pomona, CA

C. Max Lang, DVM, DACLAM

Professor and Chairman, Department of Comparative Medicine,
Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA

Richard H. Latt, DVM, DACLAM

President, Mispro Biotech Services Inc., Montreal, Quebec, Canada

Sherry M. Lewis, PhD

Nutritionist/Research Scientist,
National Center for Toxicological Research, Jefferson, AR

Carol Cutler Linder, PhD

Assistant Professor of Biology, New Mexico Highlands University, Las Vegas, NM

John A. Maher, MS, MBA, CMAR, RLATG

Senior Manager, Comparative Medicine, Pfizer, Pearl River, NY

Jörg Mayer, Dr.med.vet., MSc, MRCVS, DABVP (ECM)

Associate Professor of Zoological Medicine,
College of Veterinary Medicine, University of Georgia, Athens, GA

John Curtis Seely, DVM, DACVP

Veterinary Pathologist,
Experimental Pathology Laboratories, Research Triangle Park, NC

Jo Ellen Sherow, BS, LATG

Director, Research Compliance, Ohio University, Athens, OH

Jerald Silverman, DVM, DACLAM

Professor and Director, Department of Animal Medicine,
University of Massachusetts Medical School, Worcester, MA

Michael K. Stoskopf, DVM, PhD, DACZM

Professor and Director of Environmental Medicine Consortium,
College of Veterinary Medicine, North Carolina State University, Raleigh, NC

Debra Tiano, MA, RLATG

Facility Operations Manager,
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

Robert H. Weichbrod, PhD, MBA, RLATG

Animal Program Administrator, National Eye Institute, NIH, Bethesda, MD

Axel Wolff, MS, DVM

Director, Division of Compliance Oversight, OLAW, NIH, Bethesda, MD

Managing pain in traumatic brain injury studies

Traumatic brain injury (TBI) comprises a serious health epidemic in the US. Animal models have been designed to parallel the pathological processes that occur in humans suffering from TBI and are powerful tools for evaluating morbidities and for testing therapeutic interventions after injury. Valid modeling of TBI requires accurate replication of both the mechanical forces that cause the primary injury and the conditions that lead to secondary injuries observed in human patients. Although pain and distress should be minimized through the use of anesthetic and analgesic agents, administration of such drugs can interfere with post-injury processes and functional outcomes, threatening the validity of the research. Rowe *et al.* present evidence for the influence of anesthetics and analgesics on the natural course of brain injury in animal models of TBI and suggest that drugs be selected on the basis of IACUC-approved experimental objectives.

[See page 286](#)

Evaluating pain-related behavioral depression

Effective treatment of pain in both human and veterinary medicine begins with accurate diagnosis. Behaviors used to diagnose pain in nonverbal organisms are identified as those elicited by noxious stimuli. Preclinical studies of pharmacological compounds to treat pain require reliable, accurate assays of pain-related behavior to evaluate the analgesic potential of new drugs. In some such assays, pain is indicated by depression of a target behavior, and analgesia is indicated by recovery of the target behavior. Operant conditioning procedures can be used to train subjects to express a target behavior (e.g., pressing a lever for food), and expression of that behavior is then used to assess pain states or analgesic effects of candidate drugs. Negus reviews recent research on assays of pain-depressed behavior that use intracranial self-stimulation (ICSS), a type of operant conditioning procedure, to evaluate the expression and pharmacological modulation of pain-related behavioral depression in rats.

[See page 292](#)